Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17

1.

Cancer-Specific Synthetic Lethality between ATR and CHK1 Kinase Activities.

Sanjiv K, Hagenkort A, Calderón-Montaño JM, Koolmeister T, Reaper PM, Mortusewicz O, Jacques SA, Kuiper RV, Schultz N, Scobie M, Charlton PA, Pollard JR, Berglund UW, Altun M, Helleday T.

Cell Rep. 2016 Dec 20;17(12):3407-3416. doi: 10.1016/j.celrep.2016.12.031. No abstract available.

2.

ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A.

Williamson CT, Miller R, Pemberton HN, Jones SE, Campbell J, Konde A, Badham N, Rafiq R, Brough R, Gulati A, Ryan CJ, Francis J, Vermulen PB, Reynolds AR, Reaper PM, Pollard JR, Ashworth A, Lord CJ.

Nat Commun. 2016 Dec 13;7:13837. doi: 10.1038/ncomms13837.

3.

Cancer-Specific Synthetic Lethality between ATR and CHK1 Kinase Activities.

Sanjiv K, Hagenkort A, Calderón-Montaño JM, Koolmeister T, Reaper PM, Mortusewicz O, Jacques SA, Kuiper RV, Schultz N, Scobie M, Charlton PA, Pollard JR, Berglund UW, Altun M, Helleday T.

Cell Rep. 2016 Jan 12;14(2):298-309. doi: 10.1016/j.celrep.2015.12.032. Epub 2015 Dec 31. Erratum in: Cell Rep. 2016 Dec 20;17 (12 ):3407-3416.

4.

Development of pharmacodynamic biomarkers for ATR inhibitors.

Chen T, Middleton FK, Falcon S, Reaper PM, Pollard JR, Curtin NJ.

Mol Oncol. 2015 Feb;9(2):463-72. doi: 10.1016/j.molonc.2014.09.012. Epub 2014 Oct 13.

5.

ATR inhibitors VE-821 and VX-970 sensitize cancer cells to topoisomerase i inhibitors by disabling DNA replication initiation and fork elongation responses.

Jossé R, Martin SE, Guha R, Ormanoglu P, Pfister TD, Reaper PM, Barnes CS, Jones J, Charlton P, Pollard JR, Morris J, Doroshow JH, Pommier Y.

Cancer Res. 2014 Dec 1;74(23):6968-79. doi: 10.1158/0008-5472.CAN-13-3369. Epub 2014 Sep 30.

6.

Potentiation of tumor responses to DNA damaging therapy by the selective ATR inhibitor VX-970.

Hall AB, Newsome D, Wang Y, Boucher DM, Eustace B, Gu Y, Hare B, Johnson MA, Milton S, Murphy CE, Takemoto D, Tolman C, Wood M, Charlton P, Charrier JD, Furey B, Golec J, Reaper PM, Pollard JR.

Oncotarget. 2014 Jul 30;5(14):5674-85.

7.

Structure of human Bloom's syndrome helicase in complex with ADP and duplex DNA.

Swan MK, Legris V, Tanner A, Reaper PM, Vial S, Bordas R, Pollard JR, Charlton PA, Golec JM, Bertrand JA.

Acta Crystallogr D Biol Crystallogr. 2014 May;70(Pt 5):1465-75. doi: 10.1107/S139900471400501X. Epub 2014 Apr 30.

PMID:
24816114
8.

Targeting ATR in vivo using the novel inhibitor VE-822 results in selective sensitization of pancreatic tumors to radiation.

Fokas E, Prevo R, Pollard JR, Reaper PM, Charlton PA, Cornelissen B, Vallis KA, Hammond EM, Olcina MM, Gillies McKenna W, Muschel RJ, Brunner TB.

Cell Death Dis. 2012 Dec 6;3:e441. doi: 10.1038/cddis.2012.181.

9.

The novel ATR inhibitor VE-821 increases sensitivity of pancreatic cancer cells to radiation and chemotherapy.

Prevo R, Fokas E, Reaper PM, Charlton PA, Pollard JR, McKenna WG, Muschel RJ, Brunner TB.

Cancer Biol Ther. 2012 Sep;13(11):1072-81. doi: 10.4161/cbt.21093. Epub 2012 Jul 24.

10.

Targeting radiation-resistant hypoxic tumour cells through ATR inhibition.

Pires IM, Olcina MM, Anbalagan S, Pollard JR, Reaper PM, Charlton PA, McKenna WG, Hammond EM.

Br J Cancer. 2012 Jul 10;107(2):291-9. doi: 10.1038/bjc.2012.265. Epub 2012 Jun 19.

11.

Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR.

Reaper PM, Griffiths MR, Long JM, Charrier JD, Maccormick S, Charlton PA, Golec JM, Pollard JR.

Nat Chem Biol. 2011 Apr 13;7(7):428-30. doi: 10.1038/nchembio.573.

PMID:
21490603
12.

Discovery of potent and selective inhibitors of ataxia telangiectasia mutated and Rad3 related (ATR) protein kinase as potential anticancer agents.

Charrier JD, Durrant SJ, Golec JM, Kay DP, Knegtel RM, MacCormick S, Mortimore M, O'Donnell ME, Pinder JL, Reaper PM, Rutherford AP, Wang PS, Young SC, Pollard JR.

J Med Chem. 2011 Apr 14;54(7):2320-30. doi: 10.1021/jm101488z. Epub 2011 Mar 17.

PMID:
21413798
13.

Rapid PIKK-dependent release of Chk1 from chromatin promotes the DNA-damage checkpoint response.

Smits VA, Reaper PM, Jackson SP.

Curr Biol. 2006 Jan 24;16(2):150-9. Epub 2005 Dec 15.

14.

Identification and characterization of a novel and specific inhibitor of the ataxia-telangiectasia mutated kinase ATM.

Hickson I, Zhao Y, Richardson CJ, Green SJ, Martin NM, Orr AI, Reaper PM, Jackson SP, Curtin NJ, Smith GC.

Cancer Res. 2004 Dec 15;64(24):9152-9.

15.

Activation of the DNA damage response by telomere attrition: a passage to cellular senescence.

Reaper PM, di Fagagna Fd, Jackson SP.

Cell Cycle. 2004 May;3(5):543-6. Epub 2004 May 8.

PMID:
15034298
16.

The ATR-p53 pathway is suppressed in noncycling normal and malignant lymphocytes.

Jones GG, Reaper PM, Pettitt AR, Sherrington PD.

Oncogene. 2004 Mar 11;23(10):1911-21.

PMID:
14755251
17.

A DNA damage checkpoint response in telomere-initiated senescence.

d'Adda di Fagagna F, Reaper PM, Clay-Farrace L, Fiegler H, Carr P, Von Zglinicki T, Saretzki G, Carter NP, Jackson SP.

Nature. 2003 Nov 13;426(6963):194-8. Epub 2003 Nov 5.

PMID:
14608368

Supplemental Content

Loading ...
Support Center